Canada Dermatology Prescription Market Analysis Sample Report

Canada
Dermatology
Prescription Market
Analysis
A sample report on
Includes Market Size, Market Segmented by
Types and Key Competitors (Data forecasts
from 2023 – 2030F)
www.insights10.com

This report presents a strategic analysis of the Canada Dermatology
Prescription Market and a forecast for its development in the medium
and long term. It provides a comprehensive overview of the market value,
dynamics, segmentation, main players, growth and demand drivers,
challenges & future outlook, etc. This is one of the most comprehensive
reports about the Canada Dermatology Prescription Market, and offers
unmatched value, accuracy, and expert insights.

3
A Sample Report on Canada Dermatology Prescription Market Analysis I Confidential
Report Scope
Report Attribute Details
Number of Pages 70-80
Base Year for Estimation 2022
Forecast Period 2023-2030
Report Coverage
Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends,
Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape,
Reimbursement Scenario
Quantitative Units Revenue in USD Million/Billion (Mn/Bn)
Research Approach Secondary Research (60%), Primary Research (40%)
Click on the icon to know the detailed methodology

4
Table of Content
CONTENT PG. NO.
1. Dermatology Prescription Market Overview 6-19
1.1. Overview
1.2. Canada Overview
1.3. Economic Overview: Canada
1.4. Dermatology Prescription Market in Canada
1.5. Pharmaceuticals Market in Canada
1.6. Healthcare Scenario in Canada
1.7. Health Insurance Coverage: Canada
1.8. Budget of the Government for Public Insurance
1.9. Mergers and Acquisitions
2. Market Size and Forecasting 20-27
2.1 Market size and forecasts (Excel and Methodology)

5
Table of Content
CONTENT PG. NO.
2.2. Market Segmentation
3. Market Dynamics 28-32
3.1. Market Growth Drivers
3.2. Market Restraints
4. Competitive Landscape 33-43
4.1. Major Market Share
4.2. Key Company Profile
5. Reimbursement Scenario 44-49
5.1. Reimbursement Regulation
5.2. Reimbursement Process for Diagnosis
5.3. Reimbursement Process for Treatment
6. Methodology & Scope 50-77

Canada Dermatology Prescription Market Analysis
1. Dermatology Prescription Market Overview

7
1.1 Statistics at a Glance: The Burden of Dermatology Prescription Market in
the World
Prevalence of Dermatology Prescription
Market ▪ Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪ In this section you will get an
understanding of the topic, which includes
the prevalence of the disease, the
application of medical devices, new
technology, and other details related to the
topic
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
13 Mn+
new cases of skin
disease will be
diagnosed every day
in the world in 2023
3%
more skin diseases occurs in
females as compared to men
in the world
1.79%
is the contribution of skin
diseases to the global burden of
diseases
$23 Bn+
is the projected global
sales figure for skin
disease drugs in the
dermatology market by
2024
2 Mn+
people will die from
skin diseases in
the world in 2023
75%
skin disease deaths
worldwide are caused by
malignant skin melanoma,
making it the leading cause of
skin disease deaths

8
1.1 Statistics at a Glance: The Burden of Dermatology Prescription Market in
the World (continued)
North America
~ Market Size of
$xx Bn
Europe
~Revenue to reach
$xx Bn by 2027
Asia
-Fastest CAGR
Africa
~Market Size of
$xxBn
Canada Market
~$xx Mn Market

9
38.85 Mn
is the population of
Canada, in 2022
41
is the median age
in Canada, in 2022
2.14 Tn
is the Gross
Domestic Product
(GDP) of Canada in
2021
$8.56 k
per capita was the
amount of national
health expenditures in
Canada, 2022
▪ Please be aware that this sample report is
report
understanding of the demographics of the
country/region, which includes the
population, GDP, healthcare expenditure
and other details related to the topic
interest
1.2 Canada Overview

10
1.3 Economic Overview: Canada
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
Population of Canada , (2020-2030)
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
GDP of Canada , (2020-2030)
Population Split (2023)
55-64
0-14
15-24
25-54
65+
Male
49%
Female
51%
By Age Group
By Gender
▪ In this section you will get an understanding of the demographics
of the country/region, which includes the population, GDP,
healthcare expenditure and other details related to the topic
▪ In order to obtain access to all of the information that you are
seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will
include data, analysis, trends, and other relevant information
related to the topic or subject matter of interest
Illustrative

11
1.4 Statistics at a Glance: The Burden of Dermatology Prescription
Market in Canada
Prevalence of Dermatology Prescription
Market
▪ Please be aware that this sample report
is intended to provide you with a brief
analysis that will be presented in the
final report
understanding of the topic, which
includes the prevalence of the disease,
the application of medical devices, new
technology, and other details related to
the topic in Canada
information that you are seeking, you
will need to purchase the final report
detailed, and it will include data,
analysis, trends, and other relevant
information related to the topic or
subject matter of interest
1,300+
new cases of skin
disease will be
diagnosed every day
in Canada in 2023
10%
more skin diseases occurs in
females as compared to men
in Canada
4.5%
is the prevalence of skin disease
in Canada
$145 Mn+
dermatological
prescription dispensed in
Canada in 2023
8.7 k+
canadians are
expected to die
from skin cancer
in 2023
50%
skin disease deaths in
Canada are caused by
malignant skin melanoma,
making it the leading cause of
skin disease deaths

12
1.5 Pharmaceuticals in Canada
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Canada Pharmaceuticals Market Forecast, 2022-2030 (in $Bn)
▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be
presented in the final report
▪ In this section you will get an understanding of the overall Pharmaceuticals market in Canada , which includes the market size, current trends
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or
Illustrative

13
1.6 Healthcare Scenario in Canada
Cancer Drug Development Process: The process of developing a cancer drug is complex and involves many stages, from preclinical research
to clinical trials to regulatory approval. Here is a simplified diagram of the cancer drug development process:
o Preclinical Research: Researchers identify potential drug candidates and test them in the lab
o Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans
o Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating cancer
o Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and
effectiveness
o Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for use in the US market
Fast Track
▪ Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat
serious conditions and fill an unmet medical need
Breakthrough
Therapy
▪ A process designed to expedite the development and review of drugs which may demonstrate substantial
improvement over available therapy
Accelerated
Approval
▪ These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved
based on a surrogate endpoint
Priority Review ▪ A Priority Review designation means FDA’s goal is to take action on an application within 6 months
FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and
effectiveness. Here are four of these approaches:
Illustrative

14
1.6 Healthcare Scenario: Dermatology Patient Journey
Presentation Diagnosis Treatment Follow up
A suspected diagnosis is
usually made, based on
physical examination and
detailed patient and family
history
Prenatal screening/
Neonatal screening
Initial Diagnosis
Complete blood count
(evaluate number &
quality of RBCs, Hb &
WBCs)
Imaging (confirm bone
related changes or
respiratory problems)
Bacterial cultures of
blood, sputum, urine,
stool (detect any
infection)
Genetic testing (detect
the type of SCD)
Confirmatory Diagnosis
Prevention and management of
crisis:
• For VOC and Splenic
Sequestration: HU, Endari,
Adakveo, Oxbryta
• For infections: Antibiotics,
Vaccines
Prevention and management of
complications:
• Stroke: Chronic transfusions, HU
• Long term follow-up is required for
patients with SCD
• Annual assessment: CBC and
reticulocyte count, iron status, liver
and renal function tests, urinalysis,
LDH, vitamin D level and
neurocognitive assessment
• ESOD (End Stage Organ Damage)
evaluation starting from age 7
• Yearly Transcranial Doppler test to
determine risk of stroke
Stakeholders
PCP, paediatrician,
neonatologist,
haematologist and genetic
counsellor
PCP, pediatrician, medical geneticist,
hematologist, gynecologist and pathologist
PCP, pediatrician, medical geneticist,
cardiologist, hematologist,
endocrinologist, psychologist and
psychiatrist
PCP, pediatrician, neonatologist,
endocrinologist, cardiologist,
hematologist, orthopedist, psychologist
and psychiatrist
Depending on the organ complications,
the treatment involves different
specialists at different times
Illustrative

15
1.7 Health Insurance Coverage: Canada
1.0
18.9
18.4
35.7
2.5
3.5
10.2
54.3
66.0
91.7
8.3
VA and CHAMPVA
Any public plan
TRICARE
Marketplace
Direct-purchase
Employment-based
Any private plan
With health insurance
Uninsured
▪ In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire
calendar year
▪ More people had private health insurance (66%) than public coverage (35.7%)
▪ Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%),
followed direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%)
Coverage Type 2020 2021 Change %
Total 327,521 328,074
Any health plan 299,230 300,887 0.4
Any private plan 217,896 216,366 –0.6
Employment-based 178,737 178,285 –0.2
Direct-purchase 33,869 33,555 –0.1
Marketplace coverage 10,924 11,389 0.1
TRICARE 9,165 8,299 –0.3
Any public plan 112,925 117,095 1.2
58,541 60,226 0.5
58,778 61,940 0.9
VA and CHAMPVA 2,967 3,151 0.1
Uninsured 28,291 27,187 –0.4
% of People by Type of Health Insurance Coverage
(2021)
Number of People By Health Insurance Coverage
Illustrative

16
1.8 Budget of Canada Government for Public Insurance
Proposed Budget By Category
Outlays 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31
In Billions Of Dollars
Public $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633
Private $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926
As % Of GDP
Public 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7%
Private 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4%
▪ National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP)
▪ Public health Insurance spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE
▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE
▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE
▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE
▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020
▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020
▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020
▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health
spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7%
Illustrative

17
1.9 Mergers and Acquisitions
$6.0
$7.7
$10.5
$16.7
$6.8
$11.7
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
82
112 107 107
89
110
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020
RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend
Buyer Composition: Strategic Vs Financial (2020)
59%
41% 41%
59% 58%
42%
61%
39%
$0- $25 $25-$50 $50-$100 $100+
Strategic Buyers
Financial Buyers
Buyer Type by Deal Size
($Mn)
Illustrative

18
1.9 Mergers and Acquisitions (continued)
Company Name Type
Amount /
Duration
Year Key Pointers
Oracle acquisition of
Cerner
Acquisition $28.3 Bn June, 2022
▪ Oracle’s acquisition of Cerner is big tech’s latest foray into the
healthcare system, promising better outcomes
▪ Oracle acquire Cerner through an all-cash tender offer for $95.00
per share, or approximately $28.3 Bn in equity value
▪ Cerner is a leading provider of digital information systems used
within hospitals and health systems to enable medical
professionals to deliver better healthcare to individual patients
and communities
GSK acquisition of
BELLUS Health
Acquisition $2 Bn April 2023
▪ GSK has acquire BELLUS for US$14.75 per share of common
stock in cash representing an approximate total equity value of
US$2.0 billion
▪ BELLUS is a late-stage biopharmaceutical company working to
better the lives of patients suffering from persistent cough
▪ Acquisition further strengthens specialty medicines and
respiratory pipeline with camlipixant, a highly selective P2X3
antagonist and potential best-in-class treatment for refractory
chronic cough
Latest Deals In Canada
Illustrative

19
1.9 Mergers and Acquisitions (continued)
Company Name Type
Amount /
Duration
Year Key Pointers
Merger March 2023
Merger Jan 2023
Latest Deals In Canada
Illustrative

2. Market Size and Forecasting

21
2.1 Market size and forecasts (Excel and Methodology)
XX
XX
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Canada Dermatology Prescription Market Forecast, 2022-2030 (in $Bn)
final report
understanding of the overall Healthcare
Insurance market in Malaysia, which
includes the market size, current trends
Click on the icon to know the
methodology and assumption
2023 2024 2025 2026 2027 2028 2029 2030
Major Markets Patient
(Mn)
2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12
Canada Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73
% of Canadian Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937
Canada Market Size (Bn
$)
61 74 84 87 91 95 99 106
Illustrative

22
2.2 Snapshot of Dermatology Prescription Market Segmentation
▪ In this section you will get an understanding of the segmentations which will cover the Canada Dermatology Prescription Market
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Disease
Acne
Dermatitis
Skin Cancer
Psoriasis
Alopecia & Others
Drug Class
Antibiotics Agent
Antifungal Agents
Monoclonal
Antibodies
Corticosteroids
Retinoids
Route of
Administration
Topical
Oral
Others
Distribution
Channels
Hospital pharmacies
Retail Pharmacies
Others

23
Canada Dermatology Prescription Market Share, By Disease
(2022)
Acne
Dermatitis
Skin Cancer,
Psoriasis
Alopecia &
Others
▪ Dermatitis market in Canada is a
significant component of the overall
Dermatology Prescription market
▪ It has the maximum market share in
Canada Dermatology Prescription
market with approximately xx%
final report
2.2.1 Market Segmentation: By Disease
Illustrative

24
Canada Dermatology Prescription Market Share, By Drug Class
(2022)
2.2.2 Market Segmentation: By Drug Class
▪ Monoclonal Antibodies market in
Canada is a significant component of
the overall Dermatology Prescription
market
▪ It has the maximum market share in
Canada Dermatology Prescription
market with approximately xx%
final report
Monoclonal
Antibodies
Corticosteroids
Retinoids,
Antibiotics Agent
Antifungal
Agents
Illustrative

25
Canada Dermatology Prescription Market Share, By Route of
Administration (2022)
Topical
Oral
Others
2.2.3 Market Segmentation: By Route of Administration
▪ Topical Route of Administration has the
maximum market share in Canada
Dermatology Prescription market with
approximately xx%
final report
Illustrative

26
Canada Dermatology Prescription Market Share, By Distribution
Channels (2022)
Hospital
pharmacies
Others
Retail
pharmacies
2.2.4 Market Segmentation: By Distribution Channels
▪ Retail pharmacies has the maximum
market share in Canada Dermatology
Prescription market with approximately
xx%
final report
Illustrative

3. Market Dynamics

28
3.1 Market growth drivers
▪ Incidence of skin disease is increasing in Canada with more than 1.3 k
new skin disease cases per day is expected to be diagnosed in 2023
▪ This is driving the demand for skin disease treatments and creating
opportunities for growth in the Canada dermatology Prescription market
▪ Please be aware that this sample report is intended to provide you with a
brief overview of the kind of information and analysis that will be
presented in the final report
▪ In order to obtain access to all of the information that you are seeking,
you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
2010 2022 2030
3.1.1 Incidence of skin disease is increasing in Canada with more than 1.3 k new skin disease cases per day is
expected to be diagnosed in 2023
Incidence of Skin disease in Canada
Illustrative

29
3.1 Market growth drivers (continued)
Top countries that are leveraging
technology in their fight against Skin
Disease
United States
Japan
Germany
South Korea
China
United Kingdom
France
Canada
Australia
Israel
Switzerland
Singapore
Sweden
Netherlands
Italy
Spain
Belgium
Denmark
Austria
Norway
3.1.2 8.7 K+ Canadians are expected to die from skin cancer in 2023 thereby increasing the demand for
dermatological products
▪ Canada has a long history of investing in dermatological
research and treatment, and as a result, has become a
world leader in the field
▪ IT has a robust healthcare infrastructure, including world-
renowned research institutions, hospitals, and clinics, that
are dedicated to dermatological treatment and research
▪ One of the key factors that has allowed Canada to stay
ahead in the field of dermatology research and treatment is
the high level of investment in dermatology-related research
Illustrative

30
3.1 Market growth drivers (continued)
Increasing awareness of skin health in
Canada
3.1.3 Increasing awareness of skin health: According to the survey of Canadian Dermatology Association 62% of
Canadians are concerned about their skin health thereby rising the need of skin disease products
▪ Please be aware that this sample report is intended to
provide you with a brief overview of the kind of information
and analysis that will be presented in the final report
2010 2022 2030
Illustrative

31
3.2 Market restraints
3.2.1 In 2022, the average cost of
a new skin disease drug was
over $100,000 per year
▪ Skin disease treatments can be
very expensive and can lead to
financial burden for patients and
healthcare systems
▪ Cost of skin disease treatment
varies depending on the type of
skin disease and treatment
options
3.2.2 Average cost of developing
a new skin disease drug that is
ultimately approved by the FDA
is over $2.1 Bn
▪ Regulatory requirements for skin
care treatments can be very
stringent, which can slow down
the approval process and limit
access to new treatments
▪ Regulatory bodies, such as
Health Canada require extensive
clinical trials and safety data
before approving new cancer
treatments
▪ This can be a lengthy and costly
process, which can delay the
availability of new treatments for
patients
3.2.3 Demand for skin care is
expected to increase by 42% by 2025,
while the supply of dermatologist is
only expected to increase by 28%
▪ There is a shortage of
dermatologist in Canada , which
can limit access to skin disease
treatments and create barriers to
growth in the dermatology
market
▪ Dermatologists are physicians
who specialize in the diagnosis
and treatment of skin diseases
▪ With the increasing incidence of
skin disease, there is a growing
demand for dermatologists
▪ However, the supply of
dermatologists is not keeping
pace with the demand
Our analysis will thoroughly investigate the key restraints that may significantly impact business
operations and growth.
Illustrative

4. Competitive Landscape

33
4.1 Major Market Share
XX
Other
▪ Canada cancer market is a highly
competitive space, with many companies
developing and marketing skin care
treatments
▪ Some of the top companies in Canada skin
care market based on revenue and market
share include
▪ Bausch Health Companies Inc.’s is a
Canada based multinational
pharmaceutical company that develops,
manufactures, and markets a wide range of
prescription drugs, over-the-counter
medications, and medical devices.
▪ The company had a strong presence in the
dermatology market, with a portfolio of
products that treat a variety of skin
conditions, including acne, psoriasis, and
eczema.
Revenue of Major players in Canada Dermatology
Prescription Market ($ Mn)
Illustrative

34
4.2 Key Company Profile
▪ Here is the list of top 10 companies which
will cover in the final report
▪ Each company will have slides for
o Overview
o Key details
o Offerings
o Name of products
o Recent activities/ Press Coverage
o Distribution and Vendor Partners
o Mergers, Acquisitions and
Collaboration
o Financials
▪ If there are specific companies that you
would like to be included in the report,
please let us know via email
1 Bausch Health
3 Sanofi
5 AbbVie
7 LEO Pharma
9 Dermira
2 Galderma
4 Pfizer
6 Johnson & Johnson
8 Affimed
Atara Biotherapeutics
10
Key Note:
Illustrative

35
Founded in: 1959
HQ: Laval, Canada
Type: Private
Revenue: $7.4 Bn
Website: www.bauschhealth.com
▪ Bausch Health Companies Inc. is a multinational pharmaceutical
company that develops, manufactures, and markets a broad range
of pharmaceutical products, primarily for the eye health and
dermatology markets
▪ company's portfolio includes prescription drugs, over-the-counter
medications, and medical devices
▪ It has a global presence with operations in more than 50 countries
Solutions offered by Bausch
Health Companies Inc.'s
➢ Pharmaceuticals
➢ Direct-to-consumer sales
➢ Clinical trials
➢ Medical education
➢ Patient Support
Recent Activity / Press Coverage
In 2023,Bausch Health announced that its Salix Pharmaceuticals subsidiary will present data from XIFAXAN® (Rifaximin) clinical research at EASL's International
Liver Congress™ 2023
In 2023,Bausch Health responded to Norwich's ANDA Tentative Approval and Lawsuit Against United States Food and Drug Administration
In 2023,Bausch Health announced that its Solta Medical subsidiary has received FDA clearance for the first non-surgical, non-invasive treatment for cellulite,
Accent Ultra
4.2.1 Bausch Health Companies Inc.
Illustrative

36
4.2.1 Bausch Health Companies Inc.(continued)
Major Distribution Partners Major Vendor Partners
Partnerships Ecosystem
Illustrative

37
Company Name Type
Amount /
Duration
Year Key Pointers
Lilly
Collaboration - March, 2023
▪ Roche and Lilly will collaborate on the development of Roche
Diagnostics’ Elecsys Amyloid Plasma Panel
▪ Elecsys Amyloid Plasma Panel has demonstrated clinical
performance and is currently undergoing additional investigation
to ensure clinical validation
▪ Once approved, could help healthcare professionals to streamline
the journey to diagnosis for more patients
GenMark Diagnostics
Merger $1.8 Bn March 2021
▪ Roche to acquire GenMark Diagnostics for US$ 24.05 per share
with the expectation to close in the 2nd quarter of 2021
▪ GenMark provides molecular diagnostic tests that are designed to
detect multiple pathogens from a single patient sample
▪ GenMark’s ePlex platform delivers rapid and actionable results so
clinicians can determine the cause of infection and the most
effective treatment, potentially saving lives and alleviating the
healthcare burden
Latest Deals - Mergers and Acquisitions
4.2.1 Bausch Health Companies Inc. (continued)
Illustrative

38
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
4.2.1 Bausch Health Companies Inc.(continued)
Revenues ($Bn), 2020-2030
▪ According to Bausch Health Companies
Inc.'s 2021 financial report, the company
had sales of 564 Mn in dermatology market
in 2021
▪ This represents a 3% increase from 2020
▪ Revenue generated by Bausch Health
Companies Inc.’s in 2021 reflects the
company's continued growth and success
in the healthcare industry
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

39
4.2.2 Company 2
Founded in:
HQ:
Type:
Revenue:
Website:
Solutions offered by Company
Drugs Indications
Drugs for Cancer Recent Activity / Press Coverage
Illustrative

40
4.2.2 Company 2 (continued)
Major Distribution Partners Major Vendor Partners
Partnerships Ecosystem
Illustrative

41
Company Name Type
Amount /
Duration
Year Key Pointers
Latest Deals - Mergers and Acquisitions
Illustrative

42
xx xx xx
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
▪ Please be aware that this sample report is
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
interest
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

5. Reimbursement Scenario

44
5.1 Reimbursement Regulation
The reimbursement scenario in Canada Dermatology Prescription market is
complex and can vary depending on the specific treatment, setting of care, and
insurance coverage. Here are some key points to consider:
▪ Public Insurance:
o Public Insurance is a federal health insurance program for people aged
65 and older, as well as people with certain disabilities or health
conditions
o Public Insurance covers many skin care treatments, including
chemotherapy, radiation therapy, and some immunotherapies
o However, coverage can be subject to strict guidelines and restrictions,
such as the requirement for prior authorization
▪ Private Insurance:
o Private insurance coverage for skin care treatments can also vary
widely depending on the insurer and the specific policy
o Some policies may have high out-of-pocket costs, such as deductibles
and co-pays, while others may have more comprehensive coverage
Public Insurance provide health
insurance coverage for more than 4 in 10
Canadian
Public
Insurance
44%
Employer-Sponsored
44%
Other Private
3%
Other Public
1%
Uninsured
8%
Health Insurance Coverage, 2022
Illustrative

45
5.1 Reimbursement Regulation (continued)
▪ Affordable Care Act:
o Affordable Care Act (ACA) includes provisions to help improve access to skin care treatments by requiring insurers to cover
certain preventive services, including cancer screenings, without co-pays or deductibles
o It also includes protections for people with pre-existing conditions, such as cancer
▪ Reimbursement for New Treatments:
o Reimbursement for new skin care treatments can be a complex and lengthy process, as insurers and government programs
often require evidence of safety and effectiveness before providing coverage
o This can create challenges for companies developing and marketing new treatments
▪ Value-Based Care:
o There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the
value of treatments rather than simply the volume of treatments
o Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative

46
5.1 Reimbursement Regulation (continued)
Coverage Penetration (% Total Population) Source of Funding
Spend on Healthcare (%of Current Health Expenditure)
Reimbursement Market Trends
 Public healthcare coverage is provided by the government and includes programs like
Public Insurance
 Public Insurance is a federal program that provides healthcare coverage to individuals
who are 65 years of age or older, as well as certain younger people with disabilities
▪ Shift towards value-based care has been a significant trend in the Canada healthcare system, with payers and providers increasingly focused on improving patient
outcomes and reducing costs
▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which
incentivize providers to deliver high-quality, cost-effective care 38.9%
37.1%
35.6%
32.5%
31.5%
44.0%
46.0%
47.7%
51.0%
51.8%
2017 2018 2019 2020 2021 2022 2023
Government Expenditure
Private Health Insurance
Out of Pocket
Other
NA NA
100% 100% 100% 100% 100%
xx xx xx xx xx
2012 2013 2014 2015 2016
Public Healthcare
Coverage
Private Coverage
6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy)
14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy)
Illustrative

47
5.2 Reimbursement Process for Diagnosis of Skin Diseases
The reimbursement process in the Canada healthcare system can be complex and can vary depending on the type of healthcare
service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the
service provided
▪ Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for
reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential
errors or fraud
▪ Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service
provided, based on the negotiated payment rates or fee schedule
▪ Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost
of the service, such as deductibles, co-payments, or co-insurance
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative

48
5.3 Reimbursement Process for Treatment of Skin Diseases
The reimbursement process in the Canada healthcare system can be
complex and can vary depending on the type of healthcare service, the
healthcare provider, and the insurance coverage. Here are the general
steps involved in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a
service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance
company or other payer, requesting reimbursement for the service
provided
▪ Adjudication: The insurance company or other payer reviews the claim
to determine whether it meets the criteria for reimbursement. This can
involve verifying the patient's eligibility, reviewing the treatment
provided, and checking for any potential errors or fraud
▪ Payment: If the claim is approved, the insurance company or other
payer reimburses the healthcare provider for the service provided,
based on the negotiated payment rates or fee schedule
FDA
Private Payers Public Payers
Health Technology Assessment
Payment
Coverage
Coding
Coding depends on availability code while coverage and
payment process decisions are made through an HTA.
Market Authorization
1 3
2
Illustrative

6. Methodology & Scope

Research Methodology
▪ Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the
key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive
overview of the competitive landscape to help our clients make informed strategic decisions
▪ We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial
phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government
and regulatory published material, technical journals, trade magazines, and paid data sources
▪ For forecasting, the following parameters are considered:
❑ Market drivers and restraints along with their current and expected impacts
❑ Technological scenario and expected developments
❑ End use industry trends and dynamics
❑ Trends in the consumer behavior
❑ Regulatory scenario and expected developments
❑ Current capacity and expected capacity additions up to 2030
▪ We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected
market growth rate
▪ We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-
sensitive, reflecting the most recent value and volume of the market across regions
▪ All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs)
▪ Currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion (Mn/Bn)
Illustrative

Analysis Methodology
Our Analysis Methodology involves three critical stages:
Market Trends
Market Sizing &
Analysis
Data Triangulation &
Validation
Analysis &
Interpretation
Insights
Presentation &
Reporting
Market Data Analysis
& Statistical Model
Interpretation &
Presentation
Secondary
Research
Proprietary
Database
Data
Collection
Primary
Research

Data Triangulation & Data Validation
Bottom Up Approach
Summarization of revenue
generated from companies
to arrive at total market size
Revenue generated by products &
services offered by companies
Validation from
Primary Interview
Final
Market
Size
Top Down Approach
Final Market size break up to
rest of segmentation
Arriving at market size
of each segment
Validation from
Primary Interview
Final
Summary

Key Benefits for Stakeholders from this Report
Study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent
investment pockets
Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and
quantitative industry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided
Comprehensive quantitative analysis of the industry from 2022 to 2030F is provided to enable the stakeholders to capitalize on
the prevailing market opportunities
Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally
Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater
understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors

2022
2023-
2030
Report Attribute
Quantitative Units
Report Coverage
Customized Report
Pricing and purchase
options
Revenue in USD Million/Billion (Mn/Bn)
Market Overview, Revenue Forecast, Market
Segmentation, Growth Factors and Trends,
Company Profiles, Competitive Landscape,
Regulatory Landscape, Future Opportunities
Report Customization (3 to 5 working days)
with purchase. We will provide you with data
that is currently not a part of our scope as a
part of customization
Avail customized purchase options to meet
your exact research needs
Details
Time Frame
Base Year for
Estimation
Forecast
Period

Insights10 is a healthcare focused market
research firm founded with an aim of being an
insights driven company in the data driven world
and delivering actionable insights that can drive
decision and strategy making process for
businesses
www.insights10.com
Lifesciences Market
Research Reports you
can trust

www.insights10.com
A large database of over 30,000 syndicated
market research reports in Pharmaceuticals and
healthcare sector at global, regional as well as
country level. We also provide customized
research reports tailor made to suit your needs
Get actionable insights to
take informed business
decisions

Our qualitative, acute, and result-oriented market
research reports provide a comprehensive
understanding of the business scenario and the
latest trends related to the life sciences market
Elevate your business plans
with in-depth market analysis
and industry intelligence
www.insights10.com

Whether you are looking to expand into new
areas, develop new products, or take advantage
of new opportunities we have reports to help you
accelerate and improve your plans by identifying
unique growth prospects.
Gain a competitive edge with
Insights10's customized
healthcare research solutions
www.insights10.com

Healthcare
Services
Clinical
Trials
OTC &
Nutraceuticals
Pharmaceuticals
(Diseases & Drugs)
Digital
Health
Medical
Devices
across various categories
Market Research Reports

FEATURED REPORTS FREE SAMPLE REPORTS
TRENDING TOPICS

1200+
Reports
Published
Annually
30000+
Life science
Market Research
Reports
22000+
Country
Specific
Reports
2000+
Rare & orphan
Disease
Reports
What makes us different?

Market Overview
Growth Drivers &
Growth Restraints
Market Segmentation
Market Share Factors Driving Future Growth
Reimbursement Scenario
Policy & Regulatory
Landscape
Key Company Profiles
Epidemiology &
Disease type
Competitive Landscape
insights on
which our
reports are
based
1
2
3
4
5
6
10
9
8
7
Table of Contents

Subscription
Regulatory
Compliance
Competitive
Intelligence
Conference
Coverage
Full-Time
Engagement
Database
Service
Primary
Research
Customized
Reports
Market Research
Reports
Our Services

Research Projects Done
Over the years, we have developed an in-depth experience of executing
market analysis at global, regional & country specific level in life sciences.
Our team has
conducted market
research across 62+
global markets in
America, Europe,
Middle East, Africa and
Asia Pacific regions

Our Research Process
01 03
02 04 05
Identification of
Data
Collection of
Data
Market
Dynamics
Collaboration
of Data
Verification &
Analysis

Statistical Databases
Data
Sources
We have access to multiple highly
reliable free and subscription data
sources. We have many years of
experience to understand which
sources are more dependable for what
and which to prefer for the reliable and
latest information.
Company Websites/Annual Reports
Trade Publications
Online Databases
Published Research Reports
Whitepapers
Press Releases of Key Market Players

What kind of data is presented
in our reports?
Our reports present data, which is:
The report is
prepared using a
proven methodology
and insightful
research
Reliable
The data is prepared
by a team of highly
qualified &
experienced research
analysts & vetted by
our local associates
Expert-verified
Allowing you to
confidently make
smarter business
and strategic
decisions
Real
Covers everything
you would need to
know about the
market including
market size,
competitive analysis
& much more
Comprehensive
You do not have to
be a market expert
to understand what
really is happening
on the market and
how it works
Easy to read

“The business decision-making process is no longer as
straightforward as it used to be. It requires insights
generated at the right time, based on reliable data
interpreted in a nuanced manner for each market.
We at Insights10 are building the future of market
research and are committed to providing our clients with
the right intelligence and insights to make business
decisions quickly and efficiently.
Insighs10 is a unique platform that combines deep
domain expertise, nuanced data at a country and
functional area level, and years of experience working
with some of the best organizations in the world,
generating insights that provides substantial competitive
advantage.”
Dr. Purav Gandhi
Founder & CEO

Purav is a physician and an entrepreneur
with 12+ years of experience in Healthcare
& Life Sciences industry spanning across
strategy, market access, health informatics
and RWE, digital health, analytics and data
science. Purav studied medicine from
Gujarat University and also completed his
MBA from IIM-Kozhikode. Purav started
his career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Anish has 15+ years of experience
in management consulting in the
Life Sciences sector, and has
worked with diverse multinational
firms in the US, India, Middle East
and APAC regions. His primary
area of interest is Customer and
Market Strategy, Market Access,
and Digital Health with special
focus on emerging markets like
Africa, Middle East and APAC.
Dr. Purav Gandhi
Founder & CEO
Anish Swaminathan
Director
Leadership Team
Mukesh is an engineering graduate with
an MBA in Marketing. He is a seasoned
healthcare market research & marketing
professional with a progressive
experience of over 20 years in Life
Sciences, Pharma and Medical Device
sectors. With an in-depth understanding
of primary research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare &
completed several research projects
across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across diff.
markets (America, Europe, Africa, APAC
and Middle East). Her areas of expertise
include: Indentifying emerging trends in life
sciences industry, Competitor landscape
assessment, Disease opportunity
assessments etc. She is a pro in secondary
and primary research with a deep domain
expertise in healthcare sector.
Mukesh Nayak
Head – Marketing & Research
Ritu Baliya
Engagement Manager

Web: www.insights10.com
Email: insights@insights10.com
Call: (+91) 931 639 7935
WhatsApp: (+91) 931 639 7935
We would be happy to help.
Do you have
any questions?

www.insights10.com
Thank you
We truly appreciate your business and
look forward to serving you.

Canada Dermatology Prescription Market Analysis Sample Report

Recommended

Recommended

More Related Content

Similar to Canada Dermatology Prescription Market Analysis Sample Report

Similar to Canada Dermatology Prescription Market Analysis Sample Report (20)

More from Insights10

More from Insights10 (20)

Recently uploaded

Recently uploaded (20)

Canada Dermatology Prescription Market Analysis Sample Report